Skip to main content
eScholarship
Open Access Publications from the University of California

SARS-COV-2 Neutralizing Monoclonal Antibody Therapy in a Congregate Setting

The data associated with this publication are not available for this reason: N/A
Abstract

• Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) causes coronavirus disease 2019 (COVID-19), which can range from mild symptoms to death from respiratory failure and multi-organ dysfunction.• Correctional facilities serve as a nidus for infection due to limited space from overcrowding which is further complicated by an increasingly elderly and sick inmate population.• California, which houses nearly 95,000 inmates, has the largest inmate population of any state in the US.• LY-CoV555, also known as bamlanivimab, has been shown to reduce viral load in patients as soon as within one week of administration. • This study reports data on inmate-patients who were offered LY-CoV555 therapy based on the EUA and clinical judgement of providers rounding on COVID patients at one correctional facility. • No data exists on the utilization of LY-CoV555 and outcomes associated with its use in a congregate setting.

Main Content
For improved accessibility of PDF content, download the file to your device.
Current View